Immune booster may strengthen stem cell transplant against hodgkin lymphoma

NCT ID NCT06377540

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to a standard stem cell transplant can help people with Hodgkin lymphoma that has come back or not responded to treatment. Participants receive pembrolizumab before and after their own stem cells are transplanted, along with chemotherapy. The goal is to see if this approach improves the chance of staying cancer-free for at least a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (Keytruda)
What this could lead to: If successful, this combination could improve the chance of keeping Hodgkin lymphoma from returning after a stem cell transplant.
What could go wrong: This is a small, early-phase study (Phase 2) with only 28 participants. Adding pembrolizumab may increase side effects, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOLOGOUS STEM CELL TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOLOGOUS STEM CELL TRANSPLANT CLASSIC HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.